British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease – Labiotech.eu (blog)
Labiotech.eu (blog) |
British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease
Labiotech.eu (blog) Orchard Therapeutics has licensed a gene therapy for the rare genetic disorder X-linked chronic granulomatous disease (X-CGD) from the non-profit Généthon. London-based Orchard Therapeutics is adding a new program to its pipeline of gene therapies. The … |
